MedTrace Logo

Paroxysmal Atrial Fibrillation: Role of Inflammation, Oxidative Stress Injury and Effect of Statins

NCT00321802 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2015-01-01

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of statin therapy for prevention of atrial fibrillation (AF) in pacemaker and non-pacemaker patients with paroxysmal atrial fibrillation in the absence of significant coronary artery disease.

Conditions

Interventions

DRUG

Simvastatin

Patients take 40 mg of simvastatin per day for 6 months.

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • University of Calgary

    lead OTHER

Principal Investigators

  • Anne M Gillis, MD · University of Calgary

  • Henry J Duff, MD · University of Calgary

  • Derek V Exner, MD, MPH · University of Calgary

  • Katherine Kavanagh, MD · University of Calgary

  • L B Mitchell, MD · University of Calgary

  • Robert S Sheldon, MD, PhD · University of Calgary

  • D G Wyse, MD, PhD · University of Calgary

  • George Veenhuyzen, MD · University of Calgary

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00321802 on ClinicalTrials.gov